Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.42 |
| ▸ | TACR2 | P21452 | 3/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | MC5R | P33032 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407701 | 0.95 | OPRL1 (0.42) | OPRL1OPRM1KMT2AMEN1MAPT | |
| SCHEMBL3409859 | 0.92 | OPRL1 (0.41) | OPRL1OPRM1TACR2MC4RMC5R | |
| SCHEMBL3401667 | 0.88 | OPRM1 (0.41) | OPRL1OPRM1TACR2MC4RMC5R | |
| SCHEMBL3401750 | 0.87 | OPRL1 (0.41) | OPRL1OPRM1KMT2AMEN1MAPT | |
| SCHEMBL3434428 | 0.83 | HRH3 (0.43) | OPRL1OPRM1KMT2AMAPTHTR2A | |
| SCHEMBL4092770 | 0.83 | NPC1 (0.56) | OPRL1OPRM1TACR2MC4RMC5R | |
| SCHEMBL27836203 | 0.81 | OPRM1 (0.41) | OPRM1NPC1SMN1; SMN2KMT2AHTR2A | |
| SCHEMBL3407998 | 0.80 | OPRM1 (0.40) | OPRL1OPRM1TACR2MC4RMC5R | |
| SCHEMBL3410680 | 0.80 | NPC1 (0.41) | OPRM1TACR2NPC1SMN1; SMN2KMT2A | |
| SCHEMBL3405562 | 0.77 | CDK4 (0.57) | OPRL1OPRM1TACR2MC4RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | claimed |
| EP-2254883-B1 | SUBSTITUTED INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-11-26 | — | — | EP | claimed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | claimed |
| EP-2254883-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-01 | — | — | EP | claimed |
| WO-2009103552-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-08-27 | — | — | WO | claimed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| EP-2254883-B1 | SUBSTITUTED INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | disclosed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215828-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | OPRL1 25/4885OPRM1 30/4885TACR2 2738/4885 |
| US-20130116283-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | OPRL1 25/4885OPRM1 30/4885TACR2 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.